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Medical therapy for rcc in 2012
There are nearly 9000 new diagnoses of renal 
cell carcinoma (RCC) each year in the United 
Kingdom, and nearly 60,000 in the United 
States (Jemal et al., 2010; UK, 2011; Jemal 
et al., 2010; Cancer Research UK, 2011). 
Nephrectomy for localized disease may be 
curative, but ∼50% of patients present with 
or subsequently develop metastatic disease 
(Motzer et al., 1996; Leibovich et al., 2003), 
which is inevitably fatal. In general, these 
patients require palliative systemic therapy, 
but metastatic RCC (mRCC) has historically 
been refractory to cytotoxic and hormonal 
therapy (Harris, 1983; Yagoda and Bander, 
1989). Prior to 2007, immunotherapy with 
interferon-alpha or interleukin-2 was the 
mainstay of treatment, with modest benefits 
at best (Motzer et al., 2002b; Coppin et al., 
2005). Since then, seven molecularly targeted 
agents have been approved for use in mRCC, 
all of which have been shown in phase III 
randomized clinical trials to improve dis-
ease control and which now represent the 
standards of care (Escudier et al., 2007a,b; 
Hudes et al., 2007; Motzer et al., 2007, 2010; 
Rini et al., 2008, 2011; Sternberg et al., 
2010). Sunitinib, sorafenib, pazopanib, and 
axitinib are orally administered inhibitors 
of multiple tyrosine kinase receptors, with 
variable affinity for the vascular endothelial 
growth factor receptor (VEGF-R), and pro-
vide tumor control through suppression of 
angiogenesis, as does the monoclonal anti-
body to VEGF, bevacizumab. Temsirolimus 
and everolimus are mammalian target of 
rapamycin (mTOR) inhibitors; the mTOR 
pathway is a key component of the PI3K/
Akt pathway which mediates tumor cell pro-
liferation and survival via cell cycle regula-
tory proteins (Schmelzle and Hall, 2000; 
Fingar et al., 2004) and is also thought to 
influence angiogenesis (Del Bufalo et al., 
2006; Thomas et al., 2006). A therapeutic 
approach which targets critical biological 
signaling pathways has clearly been the most 
successful strategy to treat mRCC to date, 
however, anti-VEGF and anti-mTOR treat-
ments remain inadequate. Furthermore, 
individualized therapy for mRCC has not 
been achieved; resistance to treatment is 
a major problem for which the molecular 
basis has not been determined, and bio-
markers predictive of response or resistance 
have not been developed.
the clinico-pathological  
diversity of rcc
Renal cell carcinoma is comprised of distinct 
pathological subtypes, which to some degree 
influence tumor behavior. The predominant 
subtype, clear cell RCC, accounts for 75% of 
RCCs (Reuter, 2006), and patients with this 
histology were almost exclusively enrolled in 
the registration trials for the drugs described 
above. There is much research into the 
molecular pathogenesis of clear cell RCC, 
which is characterized by loss of function in 
the Von Hippel-Lindau (VHL) gene leading 
to accumulation of hypoxia-inducible fac-
tor (HIF) and a panel of hypoxia-respon-
sive genes such as VEGF (Kim and Kaelin, 
2004; Kaelin, 2007). Germline mutations 
in the MET oncogene are associated with 
Hereditary Papillary Renal Carcinoma 
(HRPC) and this gene may also be activated 
in sporadic Type I papillary RCC (Schmidt 
et al., 1997; Lubensky et al., 1999). Familial 
forms of Type 2 papillary RCC result from 
germline mutations in genes encoding 
metabolic enzymes, such as the Krebs cycle 
enzymes fumarate hydratase (FH) and suc-
cinate dehydrogenase B (SHDB; Toro et al., 
2003; Ricketts et al., 2008). The remaining 
subtypes – chromophobe, collecting duct, 
translocation, medullary and mucinous 
tubular, and spindle cell carcinomas – 
include some rare entities but there is still 
considerable knowledge about their patho-
biology. Specifically, chromophobe RCCs 
can occur with hair follicle hamartomas 
and pulmonary cysts as part of the autoso-
mal dominant Birt–Hogg–Dubé  syndrome, 
caused by mutations in the BHD gene FLCN 
(Nickerson et al., 2002), and KIT has been 
reported to be overexpressed in the spo-
radic form of this subtype (Yamazaki et al., 
2003; Pan et al., 2004; Yusenko et al., 2009). 
Translocation tumors are characterized by a 
breakpoint at chromosome Xp11 and gene 
fusions between TFE3 transcription factor 
and multiple genes (Martignoni et al., 2009).
Diversity of clinical outcomes in RCC 
may partly reflect this pathological varia-
tion. For example, papillary and chromo-
phobe tumors appear to be less likely to 
metastasise than clear cell tumors (Leibovich 
et al., 2010) but might also be less respon-
sive to current therapies when advanced 
(Motzer et al., 2002a; Choueiri et al., 2008; 
Plimack et al., 2010). Furthermore, patholo-
gists recognize that within individual renal 
cell tumors there is regional variation with 
respect to tumor morphology and grade. 
It is also apparent that significant hetero-
geneity of clinical behavior exists within 
a particular histological subtype of RCC. 
For example, a subset of patients with clear 
cell RCC are recognized to have limited and 
indolent metastatic disease, and may not 
require initiation of systemic treatment for 
some years (Fisher et al., 2011). In the land-
mark phase III trial of sunitinib compared 
with interferon, ∼25% of patients did not 
benefit from sunitinib treatment, despite 
all having at least a clear cell component to 
their tumor histology (Motzer et al., 2007). 
Furthermore, a recent trial of sunitinib 
exclusively in patients with RCC as a result 
of hereditary VHL disease found a response 
rate of only 33% in RCCs, and no effect of 
sunitinib on benign tumors, suggesting a 
complex relationship between the underly-
ing genetic alteration and treatment of one 
of its end-targets (Jonasch et al., 2011).
the challenge of genetic 
heterogeneity in rcc
Could these results, and the challenges asso-
ciated with current therapies for mRCC be 
partly explained on the basis of intra-and Frontiers in Oncology | Genitourinary Oncology    May 2012  | Volume 2  |  Article 49  |  2
Fisher et al.  Tumor heterogeneity in renal cell carcinoma
including PBRM1, SETD2, JARID1C, and 
UTX (van Haaften et al., 2009; Dalgliesh 
et al., 2010; Varela et al., 2011; Guo et al., 
2012; Larkin et al., 2012). Frequently, these 
are genes involved in histone and chroma-
tin modification (Larkin et al., 2012). It is 
apparent though that their mutation rate 
in clear cell RCC is often low (less than 
10%; http://www.sanger.ac.uk/perl/genet-
ics/CGP/cosmic) and therefore mutations 
are not commonly shared between patients, 
at least at the current level of sequencing 
depth possible. This work indicates the 
presence of significant inter-tumor genetic 
heterogeneity in the histological subtype 
of clear cell RCC, previously thought to be 
dominated by a driver mutation in VHL 
(Dalgliesh et al., 2010) and may present 
an obvious limitation to the “one size fits 
all” approach to systemic therapy which is 
currently offered to patients with kidney 
cancer.
the iMpact of tuMoural 
heterogeneity on treatMent and 
research
New evidence such as this clearly has pro-
found implications for clinical practice 
and research. Inter and intratumour het-
erogeneity present a major obstacle to fur-
ther improvements in medical therapy for 
mRCC. A key issue is the inability to select 
drug therapy for an individual patient, 
despite numerous studies investigating 
candidate biomarkers in RCC (reviewed in 
Vickers and Heng, 2010). This is in stark 
contrast to other solid tumor types such as 
cancers of the breast and lung and mela-
noma (Slamon et al., 2001; Kwak et al., 2010; 
Maemondo et al., 2010; Chapman et al., 
2011), where patients who will definitely 
not benefit from targeted treatment are 
more easily identifiable at the outset. It is 
possible that limited progress in predictive 
biomarker discovery and validation in RCC 
reflects the presence of complex genomic 
abnormalities which differ within regions 
of a tumor and between tumor sites. Such 
intratumour heterogeneity may result in 
tumor sampling bias and the failure to vali-
date biomarkers discovered through single 
tumor biopsy genomics analyses. Clinical 
trial designs which include rigorous tissue 
collection protocols based on multi-region 
tumor analyses to define common ubiq-
uitous genetic changes that may serve as 
more robust predictors of disease   biology, 
were analyzed by FISH and indicated the 
presence of intra-tumoural, large sub-pop-
ulations of malignant cells with and without 
VHL deletion, in at least one tumor (Moch 
et al., 1998). This finding was supported 
by results of an earlier study showing het-
erogeneous loss of chromosome 3p using 
conventional cytogenetics (van der Hout 
et al., 1993). A recent study published in this 
journal sequenced the VHL gene of paired 
primary and metastatic clear cell renal 
tumors stored as paraffin-embedded tissue 
(Vaziri et al., 2012). Seven of 10 patients’ 
samples (either primary or metastatic, con-
taining >95% tumor) were found to have 
VHL gene mutations, and one patient had 
VHL gene methylation. Four patients had 
discordant VHL genotype between primary 
and metastatic lesions, and VHL gene status 
also varied within different micro-dissected 
areas of the primary and metastatic tumors 
in two patients. Acknowledging the diffi-
culty of identifying true somatic mutations 
in genetically heterogenous specimens, 
sequence variations of the VHL gene iden-
tified in a subset of genomic DNA samples 
were independently validated by a high-
throughput technique which combines 
endonuclease scanning and Sanger sequenc-
ing (Nickerson et al., 2008). This disparity, 
and results of another study in which 32% 
of mRCC tumors bore no genetic simi-
larity to the primary (Bissig et al., 1999), 
might suggest that heterogeneous primary 
tumors result in the outgrowth of a biologi-
cally advantageous low frequency sub-clone 
which establishes the secondary disease site.
Recently we have described the com-
plex somatic mutational, genomic, and 
transcriptomic landscapes within clear cell 
RCC tumors from four patients (Gerlinger 
et al., 2012). Multiple single biopsies of pri-
mary and metastatic tumor sites enabled 
multi-region exome sequencing, revealing 
that only a minority of somatic mutations 
were present across all biopsy specimens, 
and clearly demonstrating the presence 
of spatial tumor heterogeneity involving 
nearly all levels of genetic alteration. From 
this information, a comprehensive phylo-
genetic tree of branched tumor progression 
was constructed.
inter-tuMor heterogeneity
Whole exome sequencing of clear cell renal 
tumors has recently identified a number of 
candidate cancer genes additional to VHL, 
inter-tumoral heterogeneity? This is the 
concept that distinct sub-populations 
of cancer cells exist within and between 
tumors of individual patients respectively, 
each with distinct genotypes and pheno-
types, as a result of clonal evolution of the 
tumor (Marusyk and Polyak, 2010; Navin 
et al., 2011). The underlying mechanisms 
driving intra- and inter-tumor heteroge-
neity may be different, but it seems likely 
that their impact on the ability to deliver 
personalized medicine in mRCC overlaps. 
The evidence for each will be summarized 
in the following paragraphs.
intratuMour heterogeneity
Reports of heterogeneity in DNA content 
within RCCs date back to 1985 (Ljungberg 
et al., 1985, 1996; Krech et al., 1990); in 
one study, intra-tumoural heterogeneity 
of DNA ploidy assessed by flow and static 
cytometry was found in 71% of clear cell 
RCCs (Krech et al., 1990). Some of these 
studies attempted to correlate spatial vari-
ation in DNA ploidy index with prognostic 
outcomes. Ljungberg et al. (1996) studied 
multiple samples from each of 200 RCCs 
and reported a significant proportion of 
heterogenous tumors (56%) containing 
both aneuploid and diploid cell popula-
tions. A second study also involved multiple 
samples from individual RCC nephrec-
tomy specimens, including those of clear 
cell, papillary, and chromophobe histology, 
and analyzed DNA content by flow cytom-
etry. A lower prevalence of intra-tumoural 
heterogeneity was found; 27 of 124 tumors 
(22%) contained both diploid and non-dip-
loid populations (Ruiz-Cerda et al., 1999). 
Neither of these studies observed a relation-
ship between heterogeneous distribution 
of aneuploidy within individual tumors, 
which might reflect ongoing genomic 
instability as opposed to stably aneuploid 
tumors, and survival. A negative correla-
tion between the number of DNA losses per 
RCC tumor, as determined by comparative 
genomic hybridization, and recurrence-free 
survival has been demonstrated, but this 
relationship reflects genomic complex-
ity rather than intra-tumor heterogeneity 
per se (Moch et al., 1996).
After the cloning of the VHL gene, Moch 
et al. examined intra-tumor heterogeneity 
with respect to VHL gene status in RCC. In 
this study, frozen tumor samples from 53 
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often complex and demanding in terms of 
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The mechanisms of resistance to anti-
VEGF and anti-mTOR treatments in mRCC 
are incompletely understood, but an obvi-
ous question which arises from regional 
genomic variability in tumors is whether 
intra-tumoural heterogeneity itself fosters 
treatment resistance and therapeutic fail-
ure (Carter et al., 2006; Walther et al., 2008; 
McClelland et al., 2009; Swanton et al., 2009; 
Gerlinger and Swanton, 2010; Birkbak et al., 
2011; Lee et al., 2011; Roylance et al., 2011). 
The presence of intra-tumor heterogeneity 
and its associated multiple tumor depend-
encies suggest the worrying prospect that 
multiple drugs will be required to treat one 
heterogeneous tumor.
conclusion
In summary, there is a small but increas-
ing body of literature supporting intra- and 
inter-tumor heterogeneity in RCC, pre-
dominantly in the clear cell subtype. Their 
clinical relevance has not been properly 
addressed in the era of modern genomic 
techniques. However, it is our view that the 
potential impact of tumoural heterogene-
ity on effective therapy for this disease is 
such that it is an area worthy of intensive 
research. Efforts must be focused on adapta-
tion of clinical trial design and the further 
advancement and accessibility of novel 
tumor genomics analyses derived from 
multiple tumor sites to facilitate an under-
standing of ITH and the clonal evolution of 
disease through treatment.
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